OncoMatch/Clinical Trials/NCT06492395
Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT
Is NCT06492395 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Len+DEB-TACE+HAIC and Len+DEB-TACE for hepatocellular carcinoma non-resectable.
Treatment: Len+DEB-TACE+HAIC · Len+DEB-TACE — This study is conducted to evaluate the efficacy and safety of lenvatinib plus transarterial chemoembolization (TACE) with drug-eluting beads (DEB-TACE) and hepatic artery infusion chemotherapy (HAIC) with FOLFOX regemen (Len+DEB-TACE+HAIC) versus lenvatinib plus DEB-TACE (Len+DEB-TACE) for large hepatocellular carcinoma (\> 7cm) with portal vein tumor thrombosis (PVTT).
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: TACE
previous treatment with TACE
Cannot have received: HAIC
previous treatment with HAIC
Cannot have received: TAE
previous treatment with TAE
Cannot have received: radiotherapy
previous treatment with radiotherapy
Cannot have received: systemic therapy
previous treatment with systemic therapy
Lab requirements
Blood counts
leukocyte count >3.0×10^9/L, neutrophil count >1.5×10^9/L, platelet count ≥75×10^9/L, hemoglobin 85 g/L, prothrombin time prolongation >4 s [excluded]
Kidney function
creatinine clearance rate ≤1.5× upper limit of the normal
Liver function
Child-Pugh class A/B; alanine transaminase and aspartate transaminase ≤5× upper limit of the normal
adequate hematologic and organ function, with leukocyte count >3.0×10^9/L, neutrophil count >1.5×10^9/L, platelet count ≥75×10^9/L, hemoglobin 85 g/L, alanine transaminase and aspartate transaminase ≤5× upper limit of the normal, creatinine clearance rate ≤1.5× upper limit of the normal; prothrombin time prolongation >4 s [excluded]; organ (heart and kidneys) dysfunction, unable to tolerate TACE or HAIC treatment [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify